101 related articles for article (PubMed ID: 17624022)
1. AmineDB: large scale docking of amines with CYP2D6 and scoring for druglike properties--towards defining the scope of the chemical defense against foreign amines in humans.
Costache AD; Trawick D; Bohl D; Sem DS
Xenobiotica; 2007 Mar; 37(3):221-45. PubMed ID: 17624022
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
[TBL] [Abstract][Full Text] [Related]
3. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
4. Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling.
Bazeley PS; Prithivi S; Struble CA; Povinelli RJ; Sem DS
J Chem Inf Model; 2006; 46(6):2698-708. PubMed ID: 17125210
[TBL] [Abstract][Full Text] [Related]
5. Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.
Unwalla RJ; Cross JB; Salaniwal S; Shilling AD; Leung L; Kao J; Humblet C
J Comput Aided Mol Des; 2010 Mar; 24(3):237-56. PubMed ID: 20361239
[TBL] [Abstract][Full Text] [Related]
6. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.
Martiny VY; Carbonell P; Chevillard F; Moroy G; Nicot AB; Vayer P; Villoutreix BO; Miteva MA
Bioinformatics; 2015 Dec; 31(24):3930-7. PubMed ID: 26315915
[TBL] [Abstract][Full Text] [Related]
7. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
8. Importance of amine pKa and distribution coefficient in the metabolism of fluorinated propranolol derivatives. Preparation, identification of metabolite regioisomers, and metabolism by CYP2D6.
Upthagrove AL; Nelson WL
Drug Metab Dispos; 2001 Nov; 29(11):1377-88. PubMed ID: 11602512
[TBL] [Abstract][Full Text] [Related]
9. Exploration of enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal structures using a novel computational approach.
Kjellander B; Masimirembwa CM; Zamora I
J Chem Inf Model; 2007; 47(3):1234-47. PubMed ID: 17381082
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CYP2D6 substrate interactions by computational methods.
Ito Y; Kondo H; Goldfarb PS; Lewis DF
J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
[TBL] [Abstract][Full Text] [Related]
11. Structure-based site of metabolism prediction for cytochrome P450 2D6.
Moors SL; Vos AM; Cummings MD; Van Vlijmen H; Ceulemans A
J Med Chem; 2011 Sep; 54(17):6098-105. PubMed ID: 21797232
[TBL] [Abstract][Full Text] [Related]
12. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6.
Kalgutkar AS; Zhou S; Fahmi OA; Taylor TJ
Drug Metab Dispos; 2003 May; 31(5):596-605. PubMed ID: 12695348
[TBL] [Abstract][Full Text] [Related]
13. Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528.
Kotsuma M; Hanzawa H; Iwata Y; Takahashi K; Tokui T
Drug Metab Dispos; 2008 Sep; 36(9):1938-43. PubMed ID: 18524873
[TBL] [Abstract][Full Text] [Related]
14. Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes.
Zhou X; Wang Y; Or PM; Wan DC; Kwan YW; Yeung JH
Phytomedicine; 2012 May; 19(7):648-57. PubMed ID: 22541637
[TBL] [Abstract][Full Text] [Related]
15. Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database.
Chico LK; Behanna HA; Hu W; Zhong G; Roy SM; Watterson DM
Drug Metab Dispos; 2009 Nov; 37(11):2204-11. PubMed ID: 19661215
[TBL] [Abstract][Full Text] [Related]
16. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
17. Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction.
Olubiyi OO; Olagunju MO; Obisesan AO
Curr Comput Aided Drug Des; 2017; 13(1):39-47. PubMed ID: 27632988
[TBL] [Abstract][Full Text] [Related]
18. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.
de Graaf C; Oostenbrink C; Keizers PH; van der Wijst T; Jongejan A; Vermeulen NP
J Med Chem; 2006 Apr; 49(8):2417-30. PubMed ID: 16610785
[TBL] [Abstract][Full Text] [Related]
19. Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking.
Hritz J; de Ruiter A; Oostenbrink C
J Med Chem; 2008 Dec; 51(23):7469-77. PubMed ID: 18998665
[TBL] [Abstract][Full Text] [Related]
20. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
Drug Metab Dispos; 2012 Jan; 40(1):47-53. PubMed ID: 21976621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
